Abstract
Background Reported COVID-19 cases underestimate the true number of SARS-CoV-2 infections. Data on all infections, including asymptomatic infection, are needed to guide state testing and prevention programs. To minimize biases in estimates from seroprevalence surveys and reported cases, we conducted a state-wide probability survey of Georgia households and estimated cumulative incidence of SARS-CoV-2 infections adjusted for antibody waning.
Methods From August to December 2020, we mailed kits to self-collect specimens (nasal swabs and blood spots) to a random sample of Georgia addresses. One randomly-selected adult household member completed a survey and returned specimens for virus and antibody testing. We estimated cumulative incidence of SARS-CoV-2 infections adjusted for waning antibodies, reported fraction, and infection fatality ratio (IFR). Differences in seropositivity among demographic, geographic and clinical subgroups were explored with weighted prevalence ratios (PR).
Results Among 1,370 Georgia adult participants, adjusted cumulative incidence of SARS-CoV-2 was 16.1% (95% credible interval (CrI): 13.5-19.2%) as of November 16, 2020. The reported fraction was 26.6% and IFR was 0.78%. Non-Hispanic Black (PR: 2.03, CI 1.0, 4.1) and Hispanic adults (PR: 1.98, CI 0.74, 5.31) were more likely than non-Hispanic White adults to be seropositive. Seropositivity in metropolitan Atlanta’s Fulton and DeKalb counties was similar to seropositivity elsewhere in Georgia (7.8% vs. 8.8%).
Conclusions As of mid-November 2020, one in 6 adults in Georgia had been infected with SARS-CoV-2. The scope of the COVID-19 epidemic in Georgia is likely substantially underestimated by reported cases.
Main point Using data from a probability survey of households in Georgia, USA, we estimated that 1.3 million adults aged ≥18 years experienced SARS-CoV-2 infections by November 16, 2020, of whom 1 in 4 were reported and of whom 0.78% died.
Competing Interest Statement
A.C. reports a grant from the Robert W. Woodruff Foundation during the conduct of this study and a paid consultancy with the Fulton County Board of Health, outside the submitted work. B.L. reports grants and personal fees from Takeda Pharmaceuticals, personal fees from the World Health Organization, outside the submitted work. M.F. reports consulting fees for providing statistical support during the conduct of this study. A.S. reports grants from National Institute of Allergy and Infectious Disease, NIAID (3R01AI143875-02S1), a grant from California Department of Health (CDPH), and a grant from the Robert W. Woodruff Foundation, during the conduct of this study. P.S. and T.S. report grants from the National Institutes of Health during the conduct of the study. E.H., H.B., K.T., C.D., N.L., and K.S. report no conflicts.
Funding Statement
This work was supported by the US National Institute of Allergy and Infectious Diseases (3R01AI143875-02S1), the Center for AIDS Research at Emory University (P30AI050409), and the Robert W. Woodruff Foundation through a grant to the Emory Covid-19 Response Collaborative. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The COVIDVu study was approved by the Emory University Institutional Review Board (STUDY00000695).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
COVIDVu study data are not yet publicly available. Data used for the ratio of the cases reported to cumulative incidence cases (the reported fraction) was developed from confirmed PCR+ cases in Georgia as of November 16, 2020 using data for adults ≥18 years from the Georgia Department of Public Health's public use dataset: https://ga-covid19.ondemand.sas.com/docs/ga_covid_data.zip
